SFI
EGRX

Susquehanna Fundamental Investments’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,749
Closed -$240K – 1808
2021
Q1 		$240K Sell
5,749
-7,753
-57% -$360K ﹤0.01% 1358
2020
Q4 		$629K Sell
13,502
-548
-4% -$25.6K 0.01% 1020
2020
Q3 		$597K Buy
14,050
+3,400
+32% +$149K 0.02% 822
2020
Q2 		$511K Buy
+10,650
New +$531K 0.02% 610

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Susquehanna Fundamental Investments's EGRX Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2021, closing a stake of 5,749 shares — an estimated $240K sold.

Susquehanna Fundamental Investments first reported a position in EGRX in Q2 2020 and held it in 4 quarters. The position peaked at $629K in Q4 2020. 146 funds tracked by Wall St. Rank hold EGRX as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 5,749 Eagle Pharmaceuticals, Inc. shares in Q2 2021, an estimated $240K.
  • Susquehanna Fundamental Investments first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Eagle Pharmaceuticals, Inc. position peaked at $629K in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.